Findings show a newly created drug can prevent runaway inflammation while still allowing the immune system to handle the virus, even when given late into infection.
St. Jude Children’s Research Hospital today announces the survivorship portal, part of the St. Jude Cloud ecosystem, for unparalleled data analysis and visualization.
Recent work by St. Jude Children’s Research Hospital scientists discovered which tumor cells resist treatment and why. By characterizing B-cells’ developmental stages, they designed and tested a drug combination to effectively treat resistant B-cell leukemia.
St. Jude Children’s Research Hospital scientists studying bilateral Wilms tumor found that chemotherapy resistance correlates with tumors favorable to surgery, reducing the need for additional therapy.
St. Jude Children’s Research Hospital scientists reversed an aggressive cancer, reverting malignant cells towards a more normal state.
Scientists at St. Jude Children’s Research Hospital and Dana-Farber Cancer Institute found a small set of proteins that maintain anaplastic large cell lymphoma (ALCL) identity, representing potential future therapeutic targets.
Scientists at St. Jude Children’s Research Hospital showed that the MYCN protein promotes a switch in the cellular state within the tumor microenvironment, with slow-growing mesenchymal cells swapping to the more dangerous and faster-growing adrenergic state.
Researchers from St. Jude Children’s Research Hospital and The University of Tennessee Health Sciences Center discovered two T-cell receptors in a single patient that recognizes the fusion and can guide T cells to kill all tumor cells carrying the hybrid protein in a mouse model.
Scientists at St. Jude Children’s Research Hospital have uncovered a metabolic role for cell-survival protein MCL-1, potentially explaining previous clinical trial setbacks.
St. Jude Children’s Research Hospital scientists showed inhibiting both JAK1 and JAK2 proteins improved hemophagocytic lymphohistiocytosis in models of the inflammatory syndrome.
Jordan will work with researchers to bring a greater number of new technologies, innovations and scientific breakthroughs to the clinic, enabling breakthroughs from St. Jude laboratories to benefit more patients.
Findings from St. Jude Children’s Research Hospital showed a novel dual targeting approach, where a single molecule can recognize two potential cancer-related proteins, is more effective than the single targeting approach, preventing immune escape.
Established clinician researcher will focus on novel treatments and clinical trials for difficult-to-treat childhood cancers.
The initiative aims to provide support for early-career scientists to study pediatric cancer, addressing a funding gap that drives top talent to seek more prevalent opportunities in adult cancer research or the pharmaceutical sector.
As outlined in the 2022-2027 Strategic Plan, the St. Jude Research Collaboratives program is part of an overall effort by the institution to fund collaborative research addressing complex scientific problems with transformative potential for the diseases treated at St. Jude.
The home health agency for St. Jude Children's Research Hospital outpatients earned dual certifications in both pediatrics and home health, the nation’s first such agency to achieve that distinction.
Scientists at St. Jude Children’s Research Hospital collaborated to identify and improve a chemical compound that acts as a molecular “super-glue” with broad activity across cancers.
Using CRISPR/Cas9, scientists at St. Jude Children’s Research Hospital identified RBM5 as a vital component of leukemia cell fitness, making it a promising target for drug development.
Scientists at St. Jude Children’s Research Hospital found that two common biomarkers could predict cardiomyopathy that is otherwise undetected by conventional screenings in childhood cancer survivors.
Scientists at St. Jude Children’s Research Hospital refined and enhanced the classification system for a type of pediatric leukemia using genomic and transcriptomic analysis.
Scientists at St. Jude Children’s Research Hospital collaborated with a global group to create a more inclusive and standardized criterion for acute pediatric critical illness, with implications for improving care.
Scientists at St. Jude Children’s Research Hospital created analogs of the antibiotic spectinomycin that are significantly more effective against these highly resistant bacteria.
Discover the first images of cytonemes during mammalian neural development, serving as express routes to establish morphogen gradients and tissue patterning.
Scientists at St. Jude Children’s Research Hospital reveal how G protein-coupled receptors, major therapeutic drug targets, decode critical properties of their ligands.
Scientists at St. Jude Children’s Research Hospital used cryo-electron microscopy to characterize the interaction of two proteins implicated in Parkinson’s disease.
Scientists at St. Jude Children’s Research Hospital identified genetic and epigenetic mechanisms driving predisposition to this childhood kidney cancer, impacting care and treatment.
Childhood cancer survivors have a higher prevalence of prediabetes and diabetes, which increases their risk of serious disease but also offers opportunities for prevention.
St. Jude researchers will participate in multiple oral and poster presentations and education sessions as well as moderate panels during the ASH conference.
Ranked among the top healthcare leaders and innovators across the country
Adding a modular chimeric cytokine receptor to CAR T cells increased their efficacy. Learn how this modular system could improve brain and solid tumor therapy.
Scientists at St. Jude Children’s Research Hospital identified target genes bound and regulated by HOXA9, a protein overexpressed in high-risk leukemia, extending understanding and opening new possibilities for treatment.
Immunotherapy using modified chimeric antigen receptor (CAR) T cells has greatly improved survival rates for relapsed and recurrent pediatric leukemia and lymphomas, but not brain and solid tumors.
Scientists at St. Jude Children’s Research Hospital mapped the difference in chromatin accessibility and regulation in different pediatric acute lymphoblastic leukemia subtypes.
Scientists at St. Jude Children’s Research Hospital showed that a fusion oncoprotein can drive molecularly indistinguishable rhabdomyosarcomas arising from both muscle and blood vessel cells.
St. Jude scientists mapped the gene regulatory networks responsible for progressive differentiation states of tumor-infiltrating T cells, using a technology known as single-cell CRISPR screening to knock out or genetically perturb multiple genes potentially involved.
He has also become co-leader of the Neurobiology and Brain Tumor Program within the St. Jude Comprehensive Cancer Center. These combined units comprise one of the largest clinical brain tumor programs in North America.
Scientists at St. Jude Children’s Research Hospital determined structures of a transporter protein involved in the movement of neurochemicals such as serotonin and dopamine, unearthing multiple mechanisms that can guide drug development.
St. Jude Children’s Research Hospital and ALSAC, its fundraising and awareness organization, announced new leaders of the St. Jude Board of Governors and ALSAC Board of Directors today. The announcement comes at a time when St. Jude is advancing the largest strategic investment in its 61-year history.
In 2019, St. Jude lentiviral gene therapy restored the immune system in multiple infants of X-linked severe combined immunodeficiency disorder (SCID-X1) or “bubble boy disease” at the DNA level. These children can now produce functional immune systems.
Scientists at St. Jude Children’s Research Hospital unraveled the genetics increasing the chance of survivors developing a second cancer later in life and its severity and prognosis to guide future cancer prevention.
St. Jude researchers shed light on a key player in cancer development by exploring the ability of fusion oncoproteins to form condensates in cells.
The new patient family housing building was made possible by a multi-million dollar donation from the pizza giant.
Scientists at St. Jude Children’s Research Hospital may be able to better predict outcomes and treat patients with the most common childhood cancer by more clearly defining hyperdiploidy.
Scientists at St. Jude Children’s Research Hospital found that a subset of CD8+ T cells in the brain lessens the activation of microglia and limits disease pathology in a model of Alzheimer’s disease.
Scientists at St. Jude Research Hospital unravel the mechanisms behind a key culprit in chemotherapy resistance.
St. Jude Children’s Research Hospital scientists found that immune cells present in individuals long before influenza infection predict whether the illness is symptomatic.
Award-winning NICU expert spent 21 years at Children’s Wisconsin, including four years as executive director of perinatal and neonatal services.
Scientists at St. Jude Children’s Research Hospital showed that fixed mutations within a viral population most likely stem from how easy it is to acquire that mutation (i.e., mutation accessibility) rather than just its benefit.
Former Chair of Computational Biology honored with induction into Class of 2023 Fellows.
Scientists at St. Jude Children’s Research Hospital used genomics to inform the creation of genetic and new cell-line models for hepatoblastoma, which pointed toward the DNA damage repair pathway as a promising therapeutic route.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right